186 related articles for article (PubMed ID: 26358708)
21. Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important.
Shen T; Gao C; Zhang K; Siegal GP; Wei S
Hum Pathol; 2017 Dec; 70():70-76. PubMed ID: 29031733
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
[TBL] [Abstract][Full Text] [Related]
23. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis.
Chen AC; Paulino AC; Schwartz MR; Rodriguez AA; Bass BL; Chang JC; Teh BS
Clin Breast Cancer; 2013 Apr; 13(2):133-9. PubMed ID: 23246269
[TBL] [Abstract][Full Text] [Related]
24. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
[TBL] [Abstract][Full Text] [Related]
25. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
26. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
[TBL] [Abstract][Full Text] [Related]
27. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
29. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
30. Twenty-years experience with de novo metastatic breast cancer.
Cortesi L; Toss A; Cirilli C; Marcheselli L; Braghiroli B; Sebastiani F; Federico M
Int J Cancer; 2015 Sep; 137(6):1417-26. PubMed ID: 25736070
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
[TBL] [Abstract][Full Text] [Related]
32. Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis.
Hijazi A; Mohanna M; Sabbagh S; Herrán M; Dominguez B; Sarna K; Nahleh Z
Breast Cancer Res Treat; 2024 Aug; 206(3):527-541. PubMed ID: 38683296
[TBL] [Abstract][Full Text] [Related]
33. Brain metastasis in de novo stage IV breast cancer.
He Y; Shao Y; Chen Q; Liu C; Zhu F; Liu H
Breast; 2023 Oct; 71():54-59. PubMed ID: 37499376
[TBL] [Abstract][Full Text] [Related]
34. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
36. Presence of symptoms and timing of surgery do not affect the prognosis of patients with primary metastatic breast cancer.
Ruiterkamp J; Voogd AC; Bosscha K; Roukema JA; Nieuwenhuijzen GA; Tjan-Heijnen VC; Ernst MF
Eur J Surg Oncol; 2011 Oct; 37(10):883-9. PubMed ID: 21843923
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in patients with metastatic breast cancer at the time of diagnosis.
Ren Z; Li Y; Hameed O; Siegal GP; Wei S
Pathol Res Pract; 2014 May; 210(5):301-6. PubMed ID: 24635972
[TBL] [Abstract][Full Text] [Related]
38. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Bitterman H; Yerushalmi R
PLoS One; 2015; 10(9):e0138229. PubMed ID: 26375590
[TBL] [Abstract][Full Text] [Related]
39. Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer.
Zeichner SB; Koru-Sengul T; Shah N; Liu Q; Markward NJ; Montero AJ; Glück S; Silva O; Ahn ER
Clin Breast Cancer; 2015 Feb; 15(1):e1-11. PubMed ID: 25241299
[TBL] [Abstract][Full Text] [Related]
40. Survival analysis of breast cancer subtypes in patients with spinal metastases.
Wang M; Jensen AB; Morgen SS; Wu CS; Sun M; Li H; Dahl B; Bünger CE
Spine (Phila Pa 1976); 2014 Sep; 39(19):1620-7. PubMed ID: 24979144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
